Investigating the efficacy and safety of Plasmapheresis in patients with Moderate to severe COVID-19

ABSTRACT

ConditionCOVID-19.
Covid-19;U07.1

InterventionIntervention 1 Intervention group Plasmapheresis 3-5 session (based on clinical improvement), In addition to Amp. Methylprednisolone (500 mg day1, 250 mg day 2 and day3, IV) and routine treatment according to the latest national guideline for the treatment of new corona-virus. Intervention 2 Control group Amp. Methylprednisolone (500 mg day1, 250 mg day 2 and day3, IV) and routine treatment according to the latest national guideline for the treatment of new corona-virusfor the treatment of new corona-virus.

Primary outcome:Need to receive ICU service (occurrence of shock, resistant hypoxemia despite receiving oxygen via reservoir oxygen mask, GCS score drops below 12). Timepoint The patient is monitored every 6 hours, but the results are recorded daily in the checklist. Method of measurement Physical assessment.

CriteriaInclusion criteria Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation.
The patient/Legal guardian has written consciously and freely consent to participate in the study;
The patient has moderate to severe Corona-Virus associated pneumonia;
In the first 48 hours of hospitalization, the patient did not show an improving trend;
In the first 48 hours after his/her inclusion into this study, there is no possibility of discharge from the patient's hospital;

Exclusion criteria Multi organ failure;
Pregnancy;
Lactation.